Navigation Links
Pharmacyclics, Inc. Rights Offering Oversubscribed
Date:8/5/2009

SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the preliminary results of its rights offering to purchase up to 22,500,000 shares of the Company's common stock at a subscription price of $1.28 per share, which expired as of 5:00 p.m., EDT, on July 31, 2009. The Company increased the offering size on July 29, 2009 by 3,750,000 shares, from up to 18,750,000 shares to up to 22,500,000 shares.

The subscription agent has informed the Company that based on a preliminary tabulation, as of the close of the offering the Company had received valid subscriptions from approximately 375 participants for the purchase of in excess of the 22,500,000 shares offered. The total gross proceeds anticipated to be received is $28,800,000. Of the total shares subscribed for, 70,911 shares were subscribed for pursuant to notice of guaranteed delivery, which the Company expects to have completed on or before August 5, 2009. Participants in the offering include Federated Kaufmann Funds, Perceptive Advisors LLC, Quogue Capital LLC, Special Situations Life Sciences Fund and Suttonbrook Capital Management, among other institutional investors.

The offering was oversubscribed and the proration of available over-subscription shares will be made in accordance with the procedures described in the Prospectus. Any excess payment to be refunded by us to a participating rights holder will be mailed by the subscription agent as promptly as practicable.

The Company sold 22,500,000 shares of its common stock in this Offering. This will increase the number of total outstanding shares in the company to approximately 50,000,000 shares. Computershare, the subscription agent, will issue the shares purchased in this Rights Offering as soon as practicable.

<
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Announces Subscription Price for Rights Offering
2. Pharmacyclics Files Registration Statement for Rights Offering
3. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
4. Sinobiopharma Secures Rights to Seven Key Patents
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
7. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
8. Valerie DeFillipo, Reproductive Health and Rights Expert, Joins Abt Associates
9. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
10. Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM)
11. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s ... and has been known to react more aggressively when hormones ... far from puberty, other acne causing factors like P.acnes bacteria ... threatening skin with unsightly acne scars. Adult acne treatment, Probiotic ... on how to reduce and prevent acne scarring. , ...
(Date:5/17/2013)... Brea, CA (PRWEB) May 17, 2013 IAC ... DisperSol Technologies, a start up laboratory needing to set up ... be moving to a larger facility within a year’s time. ... the knowledge that the laboratory is temporary? What is efficient ... 4 Series modular workstations from IAC Industries. The planners at ...
(Date:5/16/2013)... May 16, 2013 Oven Industries, Inc. ... controllers and temperature sensors since 1964. Expertly ... in industrial control system applications. As one ... includes a generic, control loop feedback system, which helps ... used to adjust a systematic process, using a control ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2New PID Temperature Controllers Announced by Oven Industries Inc. 2
... Oct. 6 Environmental,Tectonics Corporation,s (Amex: ETC ... announced the sale of two (2) BARA-MED(R) XD,Monoplace ... ETC is delighted to work with Saint ... The 597-bed institution,is one of the largest health ...
... 6 Caprion Proteomics Inc. announced,today that it has ... of Allergy and Infectious Diseases (NIAID), a part of ... research in the area,of infectious disease biomarkers., Under ... Caprion,will act as one of two NIAID Clinical Proteomics ...
... AALST , Belgium, AHMEDABAD, India and GOTTINGEN, ... associates,Cardiovascular Center Aalst and J.B. Dahm, MD ... Laboratories joint venture, called imaeon., imaeon ... medical images,analysis for clinical research projects, including ...
Cached Biology Technology:Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 2Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 3Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 4Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract 2Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2
(Date:5/16/2013)... and athletes choose to wear the color red when ... Psychological Science , a journal of the Association ... do with their testosterone levels. , The new study, ... of Sunderland and colleagues, demonstrated that males who chose ... higher testosterone levels than other males who chose blue. ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
Breaking Biology News(10 mins):High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... Netherlands: Transferring just one embryo at a time to ... diagnosis (PGD) and freezing at the blastocyst stage has ... that were as good as those for blastocysts that ... freezing. Their results mean that it will be possible ...
... discovered gene expression differences that could lead to better ... arthritis (JIA). Eventually such findings could enable doctors to ... more severe arthritis, while those likely to have milder ... a greater risk of side effects. The researchers were ...
... Dallas, TX (June 29, 2009) -- A team of experts ... the South African bilateral amputee track athlete, have just published ... Some of their previously confidential findings were presented to ... in May of 2008. Other findings are now being ...
Cached Biology News:Single thawed embryo transfer after PGD does not affect pregnancy rates 2Single thawed embryo transfer after PGD does not affect pregnancy rates 3Gene expression findings a step toward better classification and treatment of juvenile arthritis 2Gene expression findings a step toward better classification and treatment of juvenile arthritis 3Oscar Pistorius: Previously confidential study results released on amputee sprinter 2
1M stock solution (238mg/ml)...
...
Request Info...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide ... of rat and mouse protein kinase C ... the rat and mouse PKCzeta protein. ... does not cross-react with PKCiota/lambda. Reactivity: ...
Biology Products: